Clinical Trial Update: Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating LHP588 in patients with Alzheimer's disease associated with Porphyromonas gingivalis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Alzheimer Disease Due to Porphyromonas Gingivalis

Drugs mentioned

• LHP588

Snippet

Sponsor: Lighthouse Pharmaceuticals, Inc. | Conditions: Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis | Phase 2 | Status: RECRUITING